Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
I do not use supplier marketing copy as a source
Chemical modification of a specific inhibitor of nicotinamide N-methyltransferase to generate a membrane-permeable prodrug. Journal of Medicinal Chemistry , 61(3), 1366-1371
The MOTS-c analog CB4211 was well-tolerated in a Phase 1 trial with 85 participants and no serious adverse events
An experienced neurosurgeon or radiosurgery team can usually estimate which risks are most relevant for an individual patient by reviewing the pain type, MRI, previous procedures, baseline facial sensation, and the planned dose and target, although no risk can be predicted with complete certainty
Visible labels reduce confusion during busy clinical workflows
US$ 26.09
US$ 27.99
US$ 28.00
